NCT05186623Recruiting
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerative Colitis Using Longitudinal Data
Source: ClinicalTrials.gov · Last updated 15 Feb 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 22 Dec 2021
- Start date
- 5 Feb 2022
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Asan Medical Center
- Diseases
- Ulcerative colitis
- NCT number
- NCT05186623
What you commit to
- Study type: Observational
- Planned participants: 300
- From 5 Feb 2022 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who already received colectomy due to ulcerative colitis
Other illness
- Inflammatory Bowel Disease Unclassified
Other
- Not Korean ethnicity by family history
Who the study is looking for
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.